

sven Francque

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5997573/sven-francque-publications-by-citations.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129
papers

7,108
citations

44
h-index

83
g-index

142
ext. papers

9,695
ext. citations

6.8
avg, IF

5.9
L-index

#	Paper	IF	Citations
129	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- α Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016 , 150, 1147-1159.e5	13.3	629
128	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	40	425
127	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018 , 67, 1754-1767	11.2	376
126	Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. <i>PLoS Medicine</i> , 2014 , 11, e1001680	11.6	363
125	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014 , 5, 4309	17.4	362
124	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
123	Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. <i>Journal of Hepatology</i> , 2016 , 65, 425-43	13.4	239
122	Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. <i>Hepatology</i> , 2018 , 67, 260-272	11.2	213
121	Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Physiology</i> , 2016 , 78, 181-205	23.1	212
120	Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2015 , 149, 635-48.e14	13.3	179
119	PPAR γ gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2015 , 63, 164-73	13.4	178
118	Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide. <i>Nutrients</i> , 2017 , 9,	6.7	153
117	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020 , 72, 892-905	11.2	116
116	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
115	Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Hepatology</i> , 2014 , 59, 121-9	11.2	112
114	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020 , 73, 842-854	13.4	108
113	Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 513-9	9.4	106

112	Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids. <i>Diabetologia</i> , 2013 , 56, 2266-74	10.3	100
111	Viral hepatitis and hepatocellular carcinoma. <i>World Journal of Surgical Oncology</i> , 2005 , 3, 27	3.4	94
110	Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study. <i>Liver International</i> , 2017 , 37, 396-405	7.9	90
109	The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. <i>Frontiers in Immunology</i> , 2019 , 10, 82	8.4	86
108	Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. <i>Gastroenterology</i> , 2016 , 150, 903-10.e8	13.3	86
107	Coagulation disorders in patients with cirrhosis and severe sepsis. <i>Liver International</i> , 2003 , 23, 440-8	7.9	85
106	Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1463-1472.e6	6.9	82
105	Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. <i>Cytokine</i> , 2012 , 59, 442-9	4	76
104	Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. <i>Laboratory Investigation</i> , 2012 , 92, 1428-39	5.9	72
103	Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7325-38	5.6	70
102	C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. <i>Journal of Hepatology</i> , 2011 , 55, 660-665	13.4	68
101	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 24-39	24.2	67
100	The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. <i>Hepatology Communications</i> , 2017 , 1, 524-537	6	66
99	Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. <i>Journal of Hepatology</i> , 2015 , 62, 1047-55	13.4	64
98	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 193-203	6.1	62
97	Future remnant liver function estimated by combining liver volumetry on magnetic resonance imaging with total liver function on (99m)Tc-mebrofenin hepatobiliary scintigraphy: can this tool predict post-hepatectomy liver failure?. <i>Hpb</i> , 2016 , 18, 494-503	3.8	60
96	A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. <i>Journal of Hepatology</i> , 2017 , 66, 1158-1165	13.4	56
95	Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 3783-3794	5.6	55

94	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 970-985	18.8	54
93	Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPAR β -regulated dermatopontin. <i>JCI Insight</i> , 2017 , 2,	9.9	53
92	Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 1162-8; quiz e87	6.9	52
91	Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 19867-90	6.3	50
90	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021 , 385, 1547-1558	59.2	50
89	Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. <i>Journal of Hepatology</i> , 2016 , 65, 543-51	13.4	50
88	Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution. <i>Nature Metabolism</i> , 2019 , 1, 604-614	14.6	48
87	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020 , 88, 105889	2.3	45
86	Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1449-57 ²	44	
85	Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study. <i>Gut</i> , 2016 , 65, 1057-8	19.2	43
84	Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features. <i>PLoS ONE</i> , 2015 , 10, e0143380	3.7	43
83	Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1253-9	2.2	41
82	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021 , 74, 1097-1108	13.4	41
81	Pro-Inflammatory Cytokines but Not Endotoxin-Related Parameters Associate with Disease Severity in Patients with NAFLD. <i>PLoS ONE</i> , 2016 , 11, e0166048	3.7	40
80	Pharmacological Treatment for Non-alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2019 , 36, 1052-1074	17.4	37
79	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
78	Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model. <i>Liver International</i> , 2010 , 30, 365-75	7.9	33
77	Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. <i>Journal of Hepatology</i> , 2020 , 73, 680-693	13.4	32

76	Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. <i>International Journal of Obesity</i> , 2011 , 35, 270-8	5.5	32
75	Bilateral adrenal haemorrhage and acute adrenal insufficiency in a blunt abdominal trauma: a case-report and literature review. <i>European Journal of Emergency Medicine</i> , 2004 , 11, 164-7	2.3	32
74	Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1724-30.e5	6.9	30
73	N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. <i>Digestive and Liver Disease</i> , 2012 , 44, 315-22	3.3	29
72	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
71	Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR α . <i>Nature Communications</i> , 2019 , 10, 1684	17.4	27
70	Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, G599-G609	5.1	27
69	SULF2 strongly predisposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus. <i>Obesity</i> , 2014 , 22, 1309-16	8	23
68	Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. <i>Laboratory Investigation</i> , 2018 , 98, 1263-1275	5.9	22
67	Bacillus Calmette-Guérin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 1027-32	2.2	22
66	EFFECT OF GTS-21, AN ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONIST, ON CLP-INDUCED INFLAMMATORY, GASTROINTESTINAL MOTILITY, AND COLONIC PERMEABILITY CHANGES IN MICE. <i>Shock</i> , 2016 , 45, 450-9	3.4	22
65	Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?. <i>Obesity Reviews</i> , 2019 , 20, 353-363	10.6	22
64	Multifactorial aetiology of hepatic infarction: a case report with literature review. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 411-5	2.2	21
63	Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. <i>Frontiers in Medicine</i> , 2021 , 8, 615978	4.9	21
62	A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening. <i>PLoS ONE</i> , 2017 , 12, e0183530	3.7	19
61	Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness. <i>Hepatology</i> , 2016 , 64, 1809-1810	11.2	19
60	CD4 ⁺ ROR γ ⁺ and Tregs in a Mouse Model of Diet-Induced Nonalcoholic Steatohepatitis. <i>Mediators of Inflammation</i> , 2015 , 2015, 239623	4.3	19
59	The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. <i>Medical Hypotheses</i> , 2019 , 122, 188-197 ^{3.8}	3.8	18

58	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. <i>Atherosclerosis</i> , 2018 , 278, 82-90	3.1	17
57	Non-alcoholic fatty liver disease: A patient guideline. <i>JHEP Reports</i> , 2021 , 3, 100322	10.3	17
56	Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond. <i>World Journal of Hepatology</i> , 2015 , 7, 1905-12	3.4	16
55	Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	16
54	Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. <i>Gut</i> , 2021 ,	19.2	16
53	Beneficial Effects of Anti-Interleukin-6 Antibodies on Impaired Gastrointestinal Motility, Inflammation and Increased Colonic Permeability in a Murine Model of Sepsis Are Most Pronounced When Administered in a Preventive Setup. <i>PLoS ONE</i> , 2016 , 11, e0152914	3.7	15
52	Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH). <i>Hepatology</i> , 2021 , 73, 920-936	11.2	15
51	Measuring future liver remnant function prior to hepatectomy may guide the indication for portal vein occlusion and avoid posthepatectomy liver failure: a prospective interventional study. <i>Hpb</i> , 2017 , 19, 108-117	3.8	14
50	Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease. <i>Frontiers in Immunology</i> , 2019 , 10, 563	8.4	14
49	Liver Fibrosis Evaluation Using Real-time Shear Wave Elastography in Hepatitis C-Monoinfected and Human Immunodeficiency Virus/Hepatitis C-Coinfected Patients. <i>Journal of Ultrasound in Medicine</i> , 2016 , 35, 1299-308	2.9	13
48	Acute fatty liver of pregnancy and molecular absorbent recirculating system (MARS)-therapy: a case report. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2008 , 21, 587-9	2	13
47	Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity. <i>Journal of Hepatology</i> , 2021 , 75, 292-301	13.4	13
46	Epidemiology and treatment of autoimmune hepatitis. <i>Hepatic Medicine: Evidence and Research</i> , 2012 , 4, 1-10	3.4	12
45	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	11
44	Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease. <i>Gut</i> , 2017 , 66, 558-559	19.2	10
43	Diet Reversal and Immune Modulation Show Key Role for Liver and Adipose Tissue T Cells in Murine Nonalcoholic Steatohepatitis. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020 , 10, 467-490 ^{7,9}	7.9	9
42	Mechanisms contributing to visceral hypersensitivity: focus on splanchnic afferent nerve signaling. <i>Neurogastroenterology and Motility</i> , 2015 , 27, 1709-20	4	9
41	NASH-related increases in plasma bile acid levels depend on insulin resistance. <i>JHEP Reports</i> , 2021 , 3, 100222	10.3	9

40	Identifying Therapeutic Targets for Sepsis Research: A Characterization Study of the Inflammatory Players in the Cecal Ligation and Puncture Model. <i>Mediators of Inflammation</i> , 2018 , 2018, 5130463	4.3	9
39	Diagnostic challenges in alcohol use disorder and alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 8024-32	5.6	7
38	Adoptive Cell Transfer of Regulatory T Cells Exacerbates Hepatic Steatosis in High-Fat High-Fructose Diet-Fed Mice. <i>Frontiers in Immunology</i> , 2020 , 11, 1711	8.4	7
37	Intestinal bowel perforation and bacterial peritonitis secondary to migrated biliary and pancreatic stents. <i>Endoscopy</i> , 2008 , 40 Suppl 2, E25	3.4	6
36	The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. <i>European Cardiology Review</i> , 2014 , 9, 10-15	3.9	6
35	Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 333-339	2.4	5
34	High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. Results of the Belgian NAFLD registry. <i>Acta Gastro-Enterologica Belgica</i> , 2011 , 74, 9-16	0.6	5
33	Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. <i>BMC Gastroenterology</i> , 2017 , 17, 26	3	4
32	In Vitro Recording of Mesenteric Afferent Nerve Activity in Mouse Jejunal and Colonic Segments. <i>Journal of Visualized Experiments</i> , 2016 ,	1.6	4
31	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
30	NAFLD in lean individuals: not a benign disease. <i>Gut</i> , 2021 ,	19.2	4
29	Biopsy of focal liver lesions: guidelines, comparison of techniques and cost-analysis. <i>Acta Gastro-Enterologica Belgica</i> , 2003 , 66, 160-5	0.6	4
28	Rapidly evolving liver decompensation with some remarkable features 14 years after biliopancreatic derivation: a case report and literature review. <i>Acta Gastro-Enterologica Belgica</i> , 2010 , 73, 46-51	0.6	4
27	Perforating oesophageal carcinoma presenting as necrotizing fasciitis of the neck. <i>European Journal of Gastroenterology and Hepatology</i> , 2001 , 13, 1261-4	2.2	3
26	Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. <i>Frontiers in Pharmacology</i> , 2021 , 12, 768576	5.6	3
25	Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. <i>Cellular Immunology</i> , 2021 , 362, 104283	4.4	3
24	A targeted multi-omics approach reveals paraoxonase-1 as a determinant of obesity-associated fatty liver disease. <i>Clinical Epigenetics</i> , 2021 , 13, 158	7.7	3
23	Ultrasonically guided fine needle puncture of focal liver lesions. Review and personal experience. <i>Acta Gastro-Enterologica Belgica</i> , 1998 , 61, 158-63	0.6	3

22	Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors. <i>Acta Gastro-Enterologica Belgica</i> , 2012 , 75, 245-59	0.6	3
21	Screening for rare variants in the PNPLA3 gene in obese liver biopsy patients. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 715-721	2.4	2
20	Validation of APRI and FIB-4 score in an Antwerp cohort of chronic hepatitis C patients. <i>Acta Gastro-Enterologica Belgica</i> , 2015 , 78, 373-80	0.6	2
19	Prediction of presence of oesophageal varices just by shear-wave elastography of the liver and spleen. <i>Liver International</i> , 2017 , 37, 1406-1407	7.9	1
18	Reply to: α -reactive protein levels in non-alcoholic fatty liver disease <i>Journal of Hepatology</i> , 2012 , 56, 508-510	13.4	1
17	Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD.. <i>JHEP Reports</i> , 2022 , 4, 100412	10.3	1
16	NAFLD in type 1 diabetes: overrated or underappreciated?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021 , 12, 20420188211055557	4.5	1
15	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease		1
14	Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis. <i>Biomedicines</i> , 2020 , 8,	4.8	1
13	The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model. <i>Frontiers in Pharmacology</i> , 2021 , 12, 682065	5.6	1
12	Autophagy in Non-Alcoholic Fatty Liver Disease (NAFLD) 2016 ,		1
11	Therapeutic approaches for non-alcoholic steatohepatitis. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021 , 12, 20420188211034300	4.5	1
10	Breakthroughs in therapies for NASH and remaining challenges.. <i>Journal of Hepatology</i> , 2022 , 76, 1263-1278	13.4	1
9	Peripheral Venous, Portal Venous, Hepatic Venous, and Arterial and Intrahepatic Cytokine Levels as Biomarkers and Functional Correlations. <i>Biomarkers in Disease</i> , 2017 , 581-602		0
8	Portal Hypertension in NASH: Is It Different from Other Aetiologies?. <i>Current Hepatology Reports</i> , 2019 , 18, 134-143	1	
7	A pharmacokinetic study to guide dosing of tenofovir disoproxil fumarate during different modalities of renal replacement therapy. <i>Clinical Biochemistry</i> , 2020 , 83, 86-88	3.5	
6	Reply: To PMID 24375485. <i>Hepatology</i> , 2014 , 60, 1451	11.2	
5	Peripheral Venous, Portal Venous, Hepatic Venous, and Arterial and Intrahepatic Cytokine Levels as Biomarkers and Functional Correlations. <i>Exposure and Health</i> , 2016 , 1-22	8.8	

4	Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena. <i>Minerva Surgery</i> , 2017 , 72, 206-218	0.1
3	Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?". <i>Journal of Hepatology</i> , 2021 , 75, 1513-1514	13.4
2	Fine needle trucut biopsy in focal liver lesions: a reliable and safe method in identifying the malignant nature of liver lesions. <i>Acta Gastro-Enterologica Belgica</i> , 2007 , 70, 1-5	0.6
1	Spontaneous liver bleeding in a patient with congenital arterioportal fistulisation. Presentation of a casus princeps and review of the literature. <i>Acta Gastro-Enterologica Belgica</i> , 2013 , 76, 62-5	0.6